MiMedx Group (NASDAQ:MDXG) Lowered to "Buy" Rating by StockNews.com

StockNews.com lowered shares of MiMedx Group (NASDAQ:MDXG - Free Report) from a strong-buy rating to a buy rating in a research report released on Friday.

Separately, Cantor Fitzgerald reiterated an "overweight" rating and issued a $13.00 target price on shares of MiMedx Group in a research note on Thursday, February 27th.

MiMedx Group Trading Down 3.7%

NASDAQ MDXG traded down $0.27 during trading on Friday, reaching $6.91. 220,240 shares of the stock traded hands, compared to its average volume of 692,995. The stock's 50-day moving average price is $7.25 and its 200 day moving average price is $8.15. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. The firm has a market cap of $1.02 billion, a price-to-earnings ratio of 12.55 and a beta of 1.85. MiMedx Group has a fifty-two week low of $5.47 and a fifty-two week high of $10.14.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last released its earnings results on Wednesday, April 30th. The company reported $0.06 earnings per share for the quarter, meeting analysts' consensus estimates of $0.06. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The business had revenue of $88.21 million during the quarter, compared to the consensus estimate of $86.32 million. Analysts predict that MiMedx Group will post 0.3 EPS for the current year.

Insider Activity at MiMedx Group

In other MiMedx Group news, CAO William Frank Iv Hulse sold 54,596 shares of the business's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $430,762.44. Following the completion of the sale, the chief accounting officer now owns 440,178 shares of the company's stock, valued at $3,473,004.42. The trade was a 11.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Joseph H. Capper purchased 200,000 shares of the firm's stock in a transaction on Friday, May 2nd. The stock was bought at an average cost of $6.34 per share, with a total value of $1,268,000.00. Following the completion of the purchase, the chief executive officer now owns 529,530 shares of the company's stock, valued at approximately $3,357,220.20. This represents a 60.69% increase in their position. The disclosure for this purchase can be found here. Insiders have sold 144,018 shares of company stock worth $1,130,312 over the last ninety days. Company insiders own 1.30% of the company's stock.

Institutional Trading of MiMedx Group

A number of large investors have recently made changes to their positions in MDXG. IMG Wealth Management Inc. bought a new stake in shares of MiMedx Group in the 4th quarter worth about $28,000. Virtus Fund Advisers LLC purchased a new stake in shares of MiMedx Group in the fourth quarter valued at about $35,000. Van ECK Associates Corp purchased a new position in MiMedx Group in the fourth quarter worth approximately $40,000. Tower Research Capital LLC TRC raised its holdings in MiMedx Group by 77.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company's stock worth $63,000 after purchasing an additional 2,837 shares in the last quarter. Finally, AlphaQuest LLC purchased a new position in shares of MiMedx Group during the fourth quarter worth approximately $88,000. 79.15% of the stock is currently owned by institutional investors.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.